Evidence map›Paper›PMID 26855152›Full record

ArticleBone marrow transplantation2016

Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.

F Heinzelmann, W Bethge, D W Beelen, M Engelhard, N Kröger, P Dreger, D Niederwieser, J Finke, D Bunjes, J Tischer and 10 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 1 country.

F HeinzelmannDepartment of Radiation Oncology, University Hospital (UH) of Tübingen, Tubingen, Germany.
W BethgeDepartment of Internal Medicine II, UH of Tübingen, Tubingen, Germany.
D W BeelenDepartment of Bone Marrow Transplantation, UH of Essen, Essen, Germany.
M EngelhardDepartment of Radiotherapy, UH of Essen, Essen, Germany.
N KrögerClinic for Stem Cell Transplantation, UH of Hamburg (UKE), Hamburg, Germany.
P DregerDepartment of Medicine V, UH of Heidelberg, Heidelberg, Germany.
D NiederwieserDepartment of Hematology and Oncology, UH of Leipzig, Leipzig, Germany.
J FinkeDepartment of Hematology and Oncology, UH of Freiburg, Freiburg, Germany.
D BunjesDepartment of Internal Medicine III, UH of Ulm, Ulm, Germany.
J TischerDepartment of Internal Medicine III, UH of Munich (LMU), Munich, Germany.
G KobbeDepartment of Hematology, Oncology and Clinical Immunology, UH of Düsseldorf, Dusseldorf, Germany.
E HollerDepartment of Hematology and Oncology, UH of Regensburg, Regensburg, Germany.
M BornhäuserDepartment of Internal Medicine I, UH of Dresden, Dresden, Germany.
M StelljesDepartment of Internal Medicine A, UH of Münster, Munster, Germany.
H BaurmannDepartment for Bone Marrow Transplantation, DKD HELIOS Clinic of Wiesbaden, Wiesbaden, Germany.
A MüllerDepartment of Radiation Oncology, University Hospital (UH) of Tübingen, Tubingen, Germany.
I HaubitzData Processing Center, University of Würzburg, Wurzburg, Germany.
H SchrezenmeierInstitute of Clinical Transfusion Medicine and Immunogenetics, UH of Ulm, Ulm, Germany.
C MüllerZKRD Ulm, Ulm, Germany.
H OttingerDepartment of Bone Marrow Transplantation, UH of Essen, Essen, Germany.
Essen University Hospital · DEGerman National Bone Marrow Donor Registry · DEDüsseldorf University Hospital · DEHeidelberg University · DEImmungenetics (Germany) · DELMU Klinikum · DETU Dresden · DEUniversität Hamburg · DEUniversität Ulm · DEUniversity Children's Hospital Tübingen · DEUniversity Hospital Leipzig · DEUniversity Medical Center Freiburg · DEUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) offers the chance of cure for patients with non-transformed follicular lymphoma (FL), but is associated with the risk of non-relapse mortality (NRM). The aim of this study was to identify subgroups of FL patients who benefit from HCT. The European Society for Blood and Marrow Transplantation (EBMT) Minimum-Essential-A Data of 146 consecutive patients who received HCT for FL between 1998 and 2008 were extracted from the database of the German Registry 'DRST'. Diagnosis of FL was verified by contact with the reference pathologists. Estimated 1-, 2- and 5-year overall survivals (OS) were 67%, 60% and 53%, respectively. Day 100 NRM was 15%. Thirteen out of 33 patients (40%) with treatment-refractory disease (RD) at the time of transplantation survived long term. Univariate statistical analysis suggested limited chronic GvHD, donor age ⩽42 years and TBI-based conditioning in treatment refractory patients to correlate with favorable OS. Independent prognostic factors for OS were treatment-sensitive disease and limited chronic GvHD for the whole cohort, and additionally TBI-based conditioning for the treatment refractory subgroup. In contrast, patient age ⩾55 years had no impact on outcome. Thus, HCT for FL is associated with acceptable NRM, and offers a substantial chance of cure for patients with RD or advanced age. Donors ⩽42 years should be preferred if available.

Indexed as

AdolescentAdultAgedAge FactorsFemaleGermanyGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLymphoma, FollicularMaleMiddle AgedPrognosisRegistriesSalvage TherapySurvival Rate

Identifiers

PMID26855152
OpenAlexW2262583119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.